Elucidating the specific pharmacological mechanism of motion (MOA) of naturally transpiring compounds may be challenging. Although Tarselli et al. (60) formulated the 1st de novo synthetic pathway to conolidine and showcased this naturally developing compound effectively suppresses responses to the two chemically induced and inflammation-derived pa